Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

2,057 results found

Article
Ask Lexy

Fried Frank Harris Shriver & Jacobson LLP | USA | 6 Sep 2023

A New Era: DOJ Announces Structural Relief for Criminal Violations of the Antitrust Laws

On August 21, 2023, DOJ announced that Teva Pharmaceuticals USA, Inc. (“Teva”) and Glenmark Pharmaceuticals Inc., USA (“Glenmark”) have entered into…
Article
Ask Lexy

Cozen O'Connor | USA | 4 Aug 2023

Supreme Court Confirms: Subjective Beliefs of Falsity are Fair Game in FCA Lawsuits

On June 1, 2023, the Supreme Court unanimously held in two consolidated landmark cases, U.S. ex rel. Proctor v. Safeway Inc. and U.S. ex rel. Schutte…
Commentary
Ask Lexy

Smart & Biggar | Canada | 31 May 2023

Health Canada opens consultation on proposed application of definition of Canadian reference product based on dormant status

A generic drug manufacturer can file an abbreviated new drug submission based on a comparison to a Canadian reference product. Health Canada recently opened for consultation a proposed application of the definition of "Canadian reference product" under C.08.001.1(b) of the Food and Drug Regulations.
Article
Ask Lexy

S Horowitz & Co | European Union, Israel, United Kingdom | 23 May 2023

Novartis' PI Motion re Gilenya® Denied: Generic Entry Does Not Necessarily Cause "Catastrophic Damages" to the Brand

In a recent decision, the Israeli Supreme Court upheld a decision of the Tel Aviv District Court, which denied a motion for preliminary injunction…
Commentary
Ask Lexy

BCB | Mexico | 22 May 2023

Current situation concerning regulation of industrial property and technological innovation in Mexican animal health industry

The Linkage Gazette publicises patents relating to inventions that may be used in allopathic drugs. To date, there are no examples of drugs for veterinary use listed in the Linkage Gazette, despite fully meeting the criteria of an allopathic drug. With the existence of this huge gap in the Mexican legislation, the holders of patent rights for allopathic medicaments for veterinary use are......
Article
Ask Lexy

Covington & Burling LLP | European Union | 2 May 2023

EU Pharma Legislation Review Series: Bolar Exemption under Patent Rights

The latest draft pharmaceutical legislation published by the European Commission (“Commission”) is set to shake up the regulatory exclusivity…
Commentary
Ask Lexy

K&S Partners | India | 26 Apr 2023

Court rejects Bristol-Myers Squibb's injunction request in relation to its Apixaban patent

In a recent case, Bristol-Myers Squibb (BMS) sought a permanent injunction against Zee Laboratories (Zee Labs) for infringing BMS's patent covering the anticoagulant drug Apixaban. BMS alleged that Zee Labs was manufacturing generic Apixaban and selling it on third-party e-commerce websites and social media platforms. The court noted that BMS's patent had already expired, however, and that......
Commentary
Ask Lexy

Westerberg & Partners Advokatbyrå AB | Sweden | 24 Apr 2023

When can a preliminary injunction be granted ex parte?

This case discussed in this article examines the conditions under which a preliminary injunction can be granted ex parte. While the Patent and Market Court of Appeal ultimately found that those conditions were not met in the case at hand, the ruling poses interesting questions on the traditionally restrictive Swedish view on ex parte preliminary relief in patent cases. The case shows that a......
Commentary
Ask Lexy

Lee and Li Attorneys at Law | Taiwan | 24 Apr 2023

Court rules in favour of pharmaceutical companies that market category two new drugs

When the Patent Linkage Registration System was first launched, accounts were set up specifically for the marketing authorisation holders of category two new drugs to submit their patent information. The Food and Drug Administration (TFDA) subsequently decided to delete such accounts. The Taipei High Administrative Court recently overturned the TFDA's decisions in a judgment that will have a......
Commentary
Ask Lexy

Grau & Angulo | Spain | 17 Apr 2023

Barcelona Court of Appeal revokes preliminary injunctions that had temporarily prevented marketing of fingolimod generics

The Barcelona Court of Appeal recently revoked the preliminary injunctions that Barcelona Commercial Court No. 10 had granted at the request of Novartis against Viatris, Teva and Reddy. The injunctions had temporarily prevented these companies from marketing generic fingolimod drugs. The Court concluded that the defendants had committed no acts of unfair competition and that their actions......
Previous page 1 2 3 ...